A brief history of the global effort to develop a preventive HIV vaccine
about
Recent strategies targeting HIV glycans in vaccine designA New Scientific Paradigm may be Needed to Finally Develop an HIV VaccineThe Potential Cost-Effectiveness of HIV Vaccines: A Systematic ReviewHIV-1 and hijacking of the host immune system: the current scenario.Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine.Exploring the feasibility of multi-site flow cytometric processing of gut associated lymphoid tissue with centralized data analysis for multi-site clinical trialsInduction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.Mucosal SIV Vaccines Comprising Inactivated Virus Particles and Bacterial Adjuvants Induce CD8(+) T-Regulatory Cells that Suppress SIV-Positive CD4(+) T-Cell Activation and Prevent SIV Infection in the Macaque Model.Challenges in HIV Vaccine Research for Treatment and Prevention.Potential future impact of a partially effective HIV vaccine in a southern African setting.Questioning the HIV-AIDS Hypothesis: 30 Years of DissentThe barrier to HIV transmission provided by genital tract Lactobacillus colonization.Regulation of SIV antigen-specific CD4+ T cellular immunity via autophagosome-mediated MHC II molecule-targeting antigen presentation in mice.What Has 30 Years of HIV Vaccine Research Taught Us?Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income CountriesCharacterization and Implementation of a Diverse Simian Immunodeficiency Virus SIVsm Envelope Panel in the Assessment of Neutralizing Antibody Breadth Elicited in Rhesus Macaques by Multimodal Vaccines Expressing the SIVmac239 Envelope.A New Approach to Produce HIV-1 Envelope Trimers: BOTH CLEAVAGE AND PROPER GLYCOSYLATION ARE ESSENTIAL TO GENERATE AUTHENTIC TRIMERSHIV Vaccine: Recent Advances, Current Roadblocks, and Future Directions.Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?Virus-Like Particles Displaying Trimeric Simian Immunodeficiency Virus (SIV) Envelope gp160 Enhance the Breadth of DNA/Modified Vaccinia Virus Ankara SIV Vaccine-Induced Antibody Responses in Rhesus Macaques.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesNovel approaches in polyepitope T-cell vaccine development against HIV-1.HIV vaccines: a brief overview.Epitopes for Protective Immunity Targeting Antigens of Pathogen and/or Host (EPITAPH): Towards Novel Vaccines Against HIV and Other Medically Challenging Infections.The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.HIV-1 vaccine immunogen design strategies.Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.RNA Viruses and RNAi: Quasispecies Implications for Viral EscapeBroadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.Virus-based nanoparticles as platform technologies for modern vaccines.Neutralizing antibodies against adenovirus type 2 in normal and HIV-1-infected subjects: Implications for use of Ad2 vectors in vaccines.Trans-sialidase overcomes many antigens to be used as a vaccine candidate against Trypanosoma cruzi.Anti-Infectious Human Vaccination in Historical Perspective.Citizenship in a time of HIV: Understanding medical adult male circumcision in South Africa.More Surprises in the Development of an HIV Vaccine.The two faces of vaccine-induced immune response: protection or increased risk of HIV infection?!Development of a Preventive HIV Vaccine Requires Solving Inverse Problems Which Is Unattainable by Rational Vaccine Design.Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.Chronic Chagas disease: can prophylaxis and therapeutic vaccines crack this 'hard nut'?
P2860
Q26823603-A902DF28-7274-48F8-B408-9D764E7DCAE2Q26830360-302D6599-C5B6-4A1D-8BDB-B2D67B7C0762Q28973596-3F1FE599-DA5A-429D-AA92-FD15EA0B7CE3Q30248405-22E4DDDA-C937-4E1A-83EF-7B9CCCD5D40EQ30365998-D97C9F43-3669-4622-AD31-04691A9E1C0FQ30958546-492C7FF6-5300-4F3D-A3B9-61CE43E2FD4DQ33611645-D22B3866-53C9-46D1-B5BE-A0443C6728DDQ33820903-4610BB12-E383-4774-A688-88E902BE0853Q34148683-7A1E9267-1CD3-4173-8486-6B0EBAE09C42Q34160133-8B75616E-1701-4451-A0F5-C146E82002E9Q34229948-AA7B5F02-A2D9-402F-AB00-824796F26179Q35128826-B3BC26B1-B3F8-4AA7-B254-65AB35346252Q35132375-8DD9B8DD-92AE-4668-9FDA-02F6844609DEQ35826634-1DA6676B-2821-4093-AE9D-75580EC81412Q35885337-DD98D601-492C-4F02-9D2A-89D20EE17823Q35914362-FD3D49F8-40E4-4B62-A024-E2383388887CQ35925858-FBC32D3E-7DD0-436F-9EDA-F2CD3314D5B7Q36249933-AA3A45BF-EEBA-4116-8996-0DE45FB8E861Q36694111-F9767D90-BE86-46F3-81CB-4DF5EDCC68FAQ36827134-B09D3A76-B71A-4187-8047-5CFD8AD4731FQ37253001-FCE84C7C-C577-4177-ACE1-0B61BE753F15Q37621530-B0D15780-E6C1-4D9C-8EC8-2DC2F5DE4C92Q38168900-CFCE7879-1BC2-4304-B57C-7B0643291C05Q38210557-62F00355-C101-4984-AC13-AD1143289F3BQ38222751-98512476-B9A8-424E-B93E-4742D594E534Q38243948-9A07360C-91EB-44E4-8A39-F4FC27D22311Q38330424-4A440C67-A54F-48BD-8B28-2FED49B34564Q38533881-0EEAA744-C2CE-47B5-A442-EB9E80DFC607Q38535397-21BA778A-333A-410E-9598-7C0BA7BB9BEDQ38695294-F5402F09-5029-47F4-BA04-8C384ECEDFE9Q38702017-04553279-40A9-462B-A093-E6BABB6F66A0Q38712002-B3D5E5A8-7175-4BB2-B838-16F7792BADA7Q38735876-6ABC968A-91E3-422D-AFEB-4BF975A0FFD4Q40129444-B1FA9561-F7B7-447E-9A99-520B5C2D8F0BQ40382158-775BA894-67F6-4BFB-B75D-8887F0A7BDC7Q41966671-397F34AC-ECC6-47CA-88B4-AD9337E9C16CQ42241791-C34CE033-98BA-4DA7-A53C-50F53F81867CQ47547402-875E7E9A-FB4F-45A5-97E9-8FEB0C932DE6Q47553316-860766F8-B237-4F2D-B9D3-2F8964BA447DQ47851065-71123DDF-E1C3-4B5C-87B7-0AC431FD5B1F
P2860
A brief history of the global effort to develop a preventive HIV vaccine
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A brief history of the global effort to develop a preventive HIV vaccine
@ast
A brief history of the global effort to develop a preventive HIV vaccine
@en
A brief history of the global effort to develop a preventive HIV vaccine
@nl
type
label
A brief history of the global effort to develop a preventive HIV vaccine
@ast
A brief history of the global effort to develop a preventive HIV vaccine
@en
A brief history of the global effort to develop a preventive HIV vaccine
@nl
prefLabel
A brief history of the global effort to develop a preventive HIV vaccine
@ast
A brief history of the global effort to develop a preventive HIV vaccine
@en
A brief history of the global effort to develop a preventive HIV vaccine
@nl
P1433
P1476
A brief history of the global effort to develop a preventive HIV vaccine
@en
P2093
José Esparza
P304
P356
10.1016/J.VACCINE.2013.05.018
P407
P577
2013-08-02T00:00:00Z